AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01714206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 300 mg tablet taken orally on Days 1 through 7.
Study NCT01301521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: water-soluble cinnamon extract (Cinnulin PF)
Description: Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
Study NCT01301521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: water-soluble cinnamon extract (Cinnulin PF)
Description: Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
Study NCT02121106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Study NCT02121106 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Cognitive Remediation
Study NCT00005901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate (Aredia)
Description: Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
Study NCT04254367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learn-to-Cope
Description: Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
Study NCT01480414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4times injection
Description: bone marrow derived mono nuclear stem cell
Study NCT01480414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
Study NCT02647541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
Study NCT03371134 — intervention group
Intervention type: BIOLOGICAL
Intervention: Harvesting of muscular biopsies
Description: Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
Study NCT01748526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754) 200 mg
Description: One 200 mg tablet taken orally (by mouth) on Day 1.
Study NCT01748526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754) 300 mg
Description: One 300 mg tablet taken orally (by mouth) on Day 1.
Study NCT03402971 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.
Study NCT01978249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Study NCT01978249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary tumor resection (PTR)
Description: primary tumor resection (PTR) using open or laparoscopy or robotic surgery
Study NCT02906449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Technique
Description: Alertness training or relaxation training
Study NCT02906449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation Technique
Description: Alertness training or relaxation training
Study NCT02681796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT03960086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Podoactiva cutom-made foot orthoses
Description: Children had to use the orthotics daily during the intervention period
Study NCT03960086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Podoactiva heel lifts
Description: Children had to use the orthotics daily during the intervention period
Study NCT02231411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: V-DCC
Description: Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
Study NCT02231411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: Delayed clamping of the umbilical cord for 60 seconds
Study NCT02231411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels
Study NCT02095665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: 50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
Study NCT02095665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: 50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
Study NCT02095665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: 0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
Study NCT02095665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
Study NCT02095665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol #3
Description: 1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
Study NCT02095665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol #3
Description: 1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
Study NCT02479165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofene
Description: The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
Study NCT02479165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: The opioid group is given an oxycodone based analgesic regimen.
Study NCT02748434 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lipohypertrophy
Study NCT02748434 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal Subcutaneous Tissue
Study NCT01774097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD-301
Description: Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
Study NCT01774097 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Ten 1ml injections of placebo in the index calf and posterior, lower thigh
Study NCT01872039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perdipine injection
Description: IV
Study NCT01872039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perdipine injection
Description: IV
Study NCT01741142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-436
Description: Subjects receiving ABT-436
Study NCT01741142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Subjects receiving escitalopram
Study NCT01741142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject receiving placebo
Study NCT03896724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 adjuvanted with 25mcg Matrix-M
Description: Vaccine
Study NCT03896724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine
Description: Vaccine
Study NCT03896724 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies Vaccine
Description: Vaccine
Study NCT03896724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 adjuvanted with 50mcg Matrix-M
Description: vaccine
Study NCT03447314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection
Study NCT02728050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT02728050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02728050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT02728050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02728050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02728050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV
Study NCT02728050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT01285674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-tympanic Cisplatinum
Description: Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc. One injection per ear before each of the 3 cisplatin treatments. After injection the patient will remain with the treated ear upwards for 20 minutes and will try to avoid swallowing as much as possible.
Study NCT00369616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT002-NicQb
Study NCT00369616 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CYT002-NicQb
Study NCT03506815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: Rivaroxaban 10mg po daily x 90 (+/- 3 days)
Study NCT01598051 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto_ BAY59-7939)
Description: Patients treated with Xarelto under practical manner for SPAF.
Study NCT01192867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally QD for 56 weeks
Study NCT01192867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.
Study NCT01192867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antipshychotics (Standard of Care)
Description: Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
Study NCT01192867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipshychotics (Standard of Care)
Description: Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
Study NCT02437435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reproductive Technique Gimilio
Description: Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient.
Study NCT02437435 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intervention
Description: Patient supine, legs in triple flexion, feet on table. Physical Therapist take contact with his right hand in patient's belly for 5 minutes, without any movement.
Study NCT01137994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
Study NCT01137994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: monoclonal antibody directed to HER2 receptor
Study NCT01137994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxane chemotherapy
Study NCT01137994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Taxane chemotherapy
Study NCT01137994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinka alkaloid
Study NCT00557089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rhDNAse
Description: 2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
Study NCT00557089 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
Study NCT01761331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.~Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute.
Study NCT02663323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
Description: MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.
Study NCT03447314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
Study NCT01842698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasoundguided paravertebral catheter
Study NCT00751829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide, if necessary
Description: oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
Study NCT00751829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrendipine + hydrochlorothiazide, if necessary
Description: oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
Study NCT03866005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diabetes Visual Function Study (DiVFuSS) softgels
Description: The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).
Study NCT03866005 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: canola oil placebo softgels, 2 per day
Description: Placebo containing canola oil, 2 softgels per day
Study NCT00616200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Description: 4 weeks on strictly controlled low carbohydrate diet
Study NCT01738451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436 75 mg
Description: Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
Study NCT01738451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be administered in Part 2 of the study.
Study NCT04380961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Participants will receive single dose infusion of sirukumab on Day 1.
Study NCT04380961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo IV single dose infusion on Day 1.
Study NCT01357187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled removal of posterior instrumentation with AmnioFix
Study NCT04380961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SOC)
Description: SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
Study NCT04380961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
Study NCT03447314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3359609
Description: GSK3359609 will be available as solution for infusion.
Study NCT03447314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
Study NCT01354782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Period I: single dose of roflumilast 500 μg orally in the morning.~Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days.
Study NCT00290537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
Study NCT00290537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel
Study NCT00290537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m\^2 IV Over 3 Hours On Day 1
Study NCT01748864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etarfolatide (EC20)
Study NCT02304614 — intervention group
Intervention type: OTHER
Intervention: 3D surface imaging using a non portable and portable camera
Description: The participant will have 3D surface imaging taken of their breasts (the face will not be shown)
Study NCT02304614 — intervention group
Intervention type: OTHER
Intervention: Patient reported outcome measure (PROM): BREAST-Q
Description: The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT
Study NCT02304614 — intervention group
Intervention type: OTHER
Intervention: 2D photography
Description: The participant will have standard medical photography of their breasts (the face will not be shown)
Study NCT02304614 — intervention group
Intervention type: OTHER
Intervention: Applanation Tonometry
Description: A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
Study NCT04126577 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood samples
Description: 4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.
Study NCT01357187 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scheduled removal of posterior instrumentation without AmnioFix
Study NCT03374878 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no oral contraceptive and training
Description: 10 weeks of training in a group of oral contraceptive users
Study NCT03374878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral contraceptive and training
Description: 10 weeks of training in a group of users of oral contraceptives
Study NCT00381095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
Study NCT00381095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02775721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nursing Education related to Gastrostomy Tube Care
Description: The research nurse will provide educational intervention at each study visit utilizing the nursing process.
Study NCT02775721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Speech Therapy Education and Evaluation
Description: Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
Study NCT01920568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab 70 mg/mL
Description: Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection